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Abstract
Botulinum toxins are widely used worldwide for the treatment of medical and esthetic 
disorders. They are considered the gold standard for the treatment of muscular spasticity 
and facial dynamic wrinkles. Moreover, they are a valid alternative in the treatment of 
pain and hyperhidrosis. Several adverse events to their applications have been described, 
being the most frequent hematomas, migraines, palpebral ptosis, ectropion, or lack of 
response. Resistance to botulinum toxins in the medical field has been described, at higher 
dosages and short intervals. Nevertheless, resistance to botulinum toxin in esthetics has 
been considered traditionally anecdotic. Recent evidence suggests that resistance to botu-
linum toxins in esthetics may have higher prevalence than expected. A full analysis of the 
argument is given with up dated information regarding botulinum toxin resistance in 
medical and esthetic arenas; including elements for suspicion and diagnosis, valid alter-
natives for effective prevention, education and treatment of this misdiagnosed condition.
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1. Introduction
When botulinum toxin (BTX) was first introduced to esthetics, it was after an observation 
related to its side effects in the context of blepharospasms treatments [1]. This fact, as with 
many other drugs permitted the study, development and use of this tool into another area of 
medicine, such as cosmetic surgery.
The exponential growth of the technique, due to the medical community and patient’s inter-
ests, increased the knowledge surrounding this molecule, and the safety concerns that called 
attention at the beginning of the century due to the use of a toxin in esthetics. Moreover, it 
permitted the study of the adverse events related to the applications [2, 3]. Among the for-
mer the most common include; hematomas, migraines, palpebral ptosis, ectropion, or lack of 
response. A complete list is shown in Table 1.
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Any physician with some experience in the esthetic field understands the importance of 
patient satisfaction. Whenever we get a patient complaint after a BTX treatment, such as in 
cases of none or partial response, we face an immediate judge regarding trust, loyalty and 
professionalism. For these reasons, it is of prime importance to educate or patients concerning 
the possible causes of their complaint.
The causes of lack of response include: drug potency, toxin type, injection technique, unex-
pressive patients, cold chain alteration, toxin condition, dilution, insufficient dose, unreal 
expectations and resistance [4]. The causes are summarized in Table 2.
With the introduction to the market to new BTX type A, we have found empirically, that 
even though each toxin claims to have unique and non-interchangeable units, there are toxins 
that are more powerful than others in clinical response and lasting effect. This has called the 
attention to the drug potency parameter, especially when patients are switched from toxins 
between different treatments [5].
Clostridium botulinum bacteria produces seven serologically distinct types of botulinum 
neurotoxin (designated as types A, B, C1, D, E, F, and G). All subtypes of toxin act by pre-
venting the release of acetylcholine at the neuromuscular junction. The most potent and used 
toxin type is A. It is clear that when changing the type, very rare condition, we can expect a 
lesser response to the latter.
BT treatments adverse events
Pain
Hematoma, bruising, inflammation
Headaches
Palpebral ptosis
Pseudo ptosis
Drug interaction
Diplopia
Asymmetries
Ectropion
Allergies
Unsatisfied patient
Muscular atrophy
Dysphagia
Resistance
Table 1. Botulinum toxin (BT) treatment adverse events.
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Technical errors during the procedure such as intra dermal toxin injections or placement dis-
tant to the target muscle can manifest as lack or partial response in affected areas. Adequate 
touch ups should guarantee patient overall satisfaction.
Unexpressive patients are not good candidates for BTX treatments, because they seldom 
have problems with dynamic wrinkles, and therefore are difficult in perceiving post proce-
dure improvements with the technique.
The cold chain can be a major concern for BTX that are thermo-sensitive. Viability of this 
type of BTX at room temperature is around 240 h. According to Allegan, during BTX produc-
tion, a total of 120 h are consumed at room temperature for production, while the remaining 
120 h enables logistics (shipping and delivery to destination). Whenever the cold chain is not 
respected, it is highly probable that part of the vial content is damaged, therefore affecting the 
performance of it.
To guarantee indemnity storage should be done frozen (−5 to 8°C) until used and after recon-
stitution refrigerated at 2–8°C. The use of non-thermo-sensitive BTX could be advisable if 
Cold chain rupture is an issue.
Toxin condition can be altered whenever one of the following is verified: reconstitution >6w 
(according to Dr. Doris Hexsel’s publications), alcohol contact with toxin during disinfection, 
application of ice packs after treatment (favors vasoconstriction and lesser absorption), freezing 
the toxin after reconstitution (thermic shock damages toxin), or energic shake of the vial after 
reconstitution. Gentle handling and attention to this details should allow to prevent this event.
Dilution has been traditionally considered as a personal preference of the physician. 
Nevertheless, recent communications by this author have questioned this and open debate 
regarding the possibility of augmenting the potency of the drug by reducing the amount of 
solvent in the reconstitution, or better said, by concentrating the toxin. The effects obtained 
BT lack of response
Drug potency
Toxin type
Injection technique
Unexpressive patients
Cold chain
Toxin condition
Dilution
Insufficient dose
Un real expectations
Resistance
Table 2. Possible causes of lack of action of botulinum toxin (BT).
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through this are lesser side effects (such as migration) and prompt, more important and long 
lasting clinical benefits. The author recommends 0.5 ml as reconstitution for 125 Speywood 
Units (Azzalure-Galderma) or 50 Botox units (Vistabex-Allergan) or 1 ml for 100 Botox U 
(Botox-Allergan) or 2 ml for 300 Speywood Units (Dysport-Ipsen).
Doses are gender and individual specific. Most of the textbooks available regarding esthetic 
applications of BTX present recipes or treatment forms with practical advices about dose and 
target muscles. Nevertheless, all of this represent general recommendations to orient the clini-
cian to target the specific dose for the specific patient. In this way, a correct clinical response 
is obtained without over or under treatment of the areas involved.
Patient with unreal expectations are poor candidates for BTX treatments. A correct clinical 
history, physical exam and discussion of the procedure with photographs, of previous treat-
ments, will help to rule out them and avoid complications.
2. Resistance to chemodenervation definition
This condition is defined as the absence of benefic response and muscular atrophy after BTX 
treatment, due to an antibody response (of neutralizing antibodies) to the protein content 
within the product that neutralizes the effect.
The antibodies anti-BTX can be:
i. Neutralizing
ii. Non-neutralizing: they do not influence directly on the therapeutic effect, but augment 
foreign protein charge, increasing potentially the formation of neutralizing antibodies.
All above rank the protein content within a BTX vial as a potential trigger to develop resis-
tance. Although there are areas within the progenitor toxin complex (PTC) that have been 
identified as more prone to develop neutralizing antibodies, potentially all proteins could 
develop an immune response that may interfere action and develop resistance. The proteins 
within a vial are classified in two groups:
• Structural proteins: they are present within the toxin complex and include peripheral pro-
teins (hemagglutinin and nonhemagglutinin proteins) and core proteins of the neurotoxin 
itself. The diagram of the toxin is shown in Figure 1.
• The role of these peripheral proteins also known as Nontoxic neurotoxin associated pro-
teins (NAPS) is related to the oral ingestion of the toxin. Non-toxic-nonhemagglutinin 
proteins (NTNHA) protect the progenitor toxin complex against digestive proteases and 
gastro intestinal acidic ambient, whereas hemagglutinin proteins (HA) enhance intestinal 
absorption of it [6].
The neurotoxin molecule is a 150 kDa protein structure made up of a 100 kDa heavy chain 
and 50 kDa light chain held together by a disulfide bond and associated with a zinc atom. The 
heavy chain has the C-terminus on it and is responsible for the high affinity docking on the 
presynaptic nerve membrane, being it rapid and irreversible. The light chain is responsible 
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Figure 1. Diagram of progenitor toxin complex evidencing structural proteins (NTNHA, HA and neurotoxin).
Product Toxin 
type
Lab Formulation Units/vial Excipients Storage
Azzalure A Galderma Lyophilisate 125 Speywood 125 μg SA
2.5 mg Lactose
2–8°C
Dysport A Ipsen Lyophilisate 300 Speywood 125 μg SA
2.5 mg Lactose
2–8°C
Vistabex A Allergan Vaccum dried 
powder
50 Allergan 500 μg SA
0.9 mg NaCl
2–8°C
Botox A Allergan Vaccum dried 
powder
100 Allergan 500 μg SA
0.9 mg NaCl
2–8°C
Bocouture A Merz Lyophilisate 50 Merz 1000 μg SA
Cane sugar 5 mg
RT
Xeomin A Merz Lyophilisate 100 Merz 1000 μg SA
25 mg Sucrose
RT
CBTX-A* A Lanzho Institute of 
Biological Products
Lyophilisate 100 20 mg gelatin
25 mg dextran
25 mg SUCROSE
−5/−20°C
Myobloc/
Neurobloc
B Solstice Liquid 5000, 10,000, 
or 20,000
500 μg/ml SA
10 nM Na succinate
100 nM Na chloride, Na 
octanoate, pH = 5.6
2–8°C
*CBTX-A, Chinese BoNT/A complex; SA, serum albumin, RT, room temperature.
Table 3. Principal characteristics of most common BTX products available.
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for the intracellular cleavage of proteins required for transmission of acetylcholine across the 
neuromuscular junction. Regions of the light chain have been recognized by human anti-
toxin antibodies from cervical dystonia patient’s immunoresistant to toxin treatment [7–11]. 
The antigenic structure of the active toxin recognized by human antibodies relies predomi-
nantly on three peptides within the light chain named L11, L14 and L18. These three antigenic 
regions reside in close proximity to the belt of the heavy chain. The regions L11 and L18 are 
accessible in both the free light chain and the holotoxin forms, while L14 appears to be less 
accessible in the holotoxin. Antibodies against these regions could prevent delivery of the 
L-chain into the neurons by inhibition of the translocation.
• Excipients proteins: they are present in most commercial products available in the market 
in the form of serum albumin, the only exception being the Chinese BTX-A, that uses gela-
tin as protein stabilizer. This plasmatic transport protein is regularly used in hemodynamic 
treatments as a volume stabilizer. Moreover, it is present in diary and eggs and is suscep-
tible of allergenic response. Nevertheless, most of the allergic reactions or intolerances are 
due to lacto globulin and not serum albumin. The role of this protein in the vials serves 
especially as protein stabilizer to prevent the adsorption of the toxin to glass and plastic 
surfaces and probably to maintain the toxin in the target area after being injected. In this 
case, according to the author theory, would be the principal responsible of limiting micro 
diffusion. On the other hand, macro diffusion, associated with the most feared complica-
tion such as palpebral ptosis, depends on the solvent quantity (or dilution) for the vial 
preparation [12].
The other excipients are not important regarding resistance to BTX. Details of the principal 
characteristics of the most common BTX products available in the market is given in Table 3. 
Excipients within the vials respect a very strict proportion, and when altered could affect 
lasting effect.
3. BTX resistance risk factors
The principal aspects recognized are:
• Higher doses: this characteristic exposes medical patients to a major risk in comparison to 
esthetic applications, and wrongly induced physicians to believe that resistance was not 
possible in the esthetic field [13–15]. As recently demonstrated in the author’s publication, 
resistance in esthetics is not only possible, but more frequent than expected.
• Short treatment intervals: according to this feature, treatments should only be done every 
6 months if possible and touch ups should be limited within the first week and only once.
• Individual predisposition: some patients are more susceptible than others in resistance de-
velopment. As with many autoimmune disorders, females seem more prone to be affected, 
although males usually are treated with higher doses of BTX. A correct clinical history may 
identify allergic or autoimmune disorders, which could put the patient at increased risk of 
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resistance and could constitute a relative contraindication for the treatment. The exact phe-
notype of this patients have not been fully understood or identified yet, and genetic tests 
could give some information about it in the future.
4. Diagnosis
BTX resistance is based in 2 pillars: clinical suspicion and laboratory tests.
The former is of vital importance as you can only diagnose what you have been trained to 
see or suspect. Patients present generally upset, after 2 or more BTX treatments in which 
they refer that the treatment did not gave the expected result, did not work or the inten-
sity or duration of the clinical response was less than expected or experimented in previous 
treatments.
The common physician action here is to raise the dose previously used or to change the com-
mercial preparation employed (always staying in BTX-A), increasing both patient anxiety and 
resistance.
Laboratory test can be clinical, in vivo or in vitro [16].
Clinical tests are intramuscular measurements of compound potential action and are indirect 
and not specific.
In vivo tests are considered the gold standard for the diagnosis, since they represent the only 
FDA approved. The most popular is the bioassay or mouse lethality test. They give quantita-
tive results about the presence of Antibodies in the patient’s serum. The test consist in the 
injection of the suspected patient serum intravenously or intra peritoneal in mouse together 
with the inoculation of BTX-A. Toxicity or death of the animals is measured and is expected if 
no or low titers antibodies are present within the patient serum.
It has medium sensibility and specificity, takes 2–4 days, and is rather expensive (140 Euros). 
Moreover, is complicated (not available in many regions), and has obvious animal rights issues.
The test is available in Hannover Germany in Toxogen Lab (www.toxogen.de). The sample 
of patient blood (14 ml) or serum (5 ml) not frozen nor heparinized should be sent in a cold 
plastic container through express mail. The test form is presented in Figure 2.
In vitro tests include the mouse diaphragm assay (MDA), enzyme-linked immunosorbent 
assays (ELISA) or the immunoprecipitation assay (IPA). They are not specific and measure 
only one part of the reaction.
A new in vitro test known as Neuronal Cell-based Botulinum Neurotoxin Assay, based on 
histological preparations of mouse neural cord is available. It guarantees less animal’s death 
and sufferance (72 tests/animal) and is highly sensitive, specific and safe. For these reasons, it 
may be the test of the future [17].
A summary of diagnostic tests is given in Table 4.
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Figure 2. Resistance test form.
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5. Prevention
The prophylaxis for resistance development includes: adequate treatment intervals, person-
alized treatments, minimal effective dose, periodical tests execution, patient education, vast 
therapeutic arsenal, treatment onset >30 years (esthetic) and to avoid patients with strong 
allergic or autoimmune phenotype.
As previously mention, treatment intervals should be 6 months, with the minimum possible 
interval around 3 months, and touch should be done within the first week after the treatment 
and only once.
The treatments should be personalized, escaping from traditional formulas, using the mini-
mal effective dose for the target area and avoiding treating areas with little or no mobility or 
wrinkles (example: procerus muscle in some patients). It is important to keep track on the 
individual treatment schema and lasting of the clinical effect, as the duration can be the first 
indicator that there is some resistance development.
In case of suspicion, serologic test should be promptly indicated.
Patients should be informed about this condition and about the other therapeutic alternatives, 
like bioplasties or laser, which can be combined to avoid the neurotoxin abuse, or “neurotoxin 
dependent syndrome”. In this way we will obtain natural results and maintain facial mobility 
without wrinkles. The idea is to make patients to consider both; skin quality and facial wrinkles.
Some congress communications in Latin America, have shown the use of BTX in 16 years old 
patients for wrinkles prevention. In this case, although it may be effective, it would expose the 
patient to a very long way on toxin treatments, and potential resistance [18]. For this reason, 
Type Name Characteristics
Clinical Compound Action Potential Intramuscular measurements (Frontalis, Extensor Digitorum 
Brevis, SCM)
Indirect
↓Sp
In vivo Mouse Lethality Test Gold Std, quantitative, FDA approved
Medium Se/Sp, complicated
Expensive
2–4 days
Animal rights
In vitro MDA
ELISA
IPA
↓Sp
Single phase measurements
Neuronal Cell-based Botulinum 
Neurotoxin Assay
Histologic sample of rat neural cord
<N° (72 test/animal) & animal suffering
↑Se/Sp
Safer, future
SCM, sternocleidomastoid muscle; ↑, high; ↓, low; Se, sensitivity; Sp, specificity; MDA, mouse diaphragm assay; ELISA, 
enzyme-linked immunosorbent assays; IPA, immunoprecipitation assay.
Table 4. Diagnostic test for BTX-A resistance.
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in this group wrinkles prevention is advised through a correct cosmetic skin care, sun protec-
tion and nutrition. We recommend cosmetic BTX treatments not to be started before the 3rd 
decade of life.
Finally, within the clinical history attention should focus on the autoimmune and aller-
gic phenotypes. Although it is not quite clear, both groups would have an important ten-
dency to develop resistance and should be considered a partial contraindication for BTX 
applications.
Each case should be discussed and cost benefit decision should be taken with an informed 
patient.
6. Treatment
Treatment alternatives include botulinum toxin type B (BTX-B), medical electronic and infil-
trative devices, peelings and cosmetic skin care. A special mention should be given to psycho-
logical support for the patient with BTX resistance.
BTX-B, also known as Myobloc (US) or Neurobloc (EC) (Solstice Laboratories) is a toxin of 
diverse type and although it has a quicker onset than BTX-A is not as potent and the effects 
will last less. Even though antibody titers tend to diminish in time, new treatments with 
BTX-A are not suggested. Other important fact to mention is that the drug is intended in 
Europe for Cervical Dystonia, and not for esthetic use, so it is very difficult to obtain the prod-
uct in a private practice setting.
Medical electronic devices embrace non-ablative or ablative procedures. Non-ablative meth-
odologies include infrared, radiofrequency and localized ultrasounds, only to name a few. 
Ablative procedures include lasers, like CO
2
 or erbium.
All above improve collagen synthesis and skin reorganization and may increase dermic thick-
ness reducing visible wrinkles.
Infiltrative devices group bioplasties (to improve skin hydration or metabolism), or needling 
through derma rollers or dermic pens.
Peelings may enhance skin renewal and tone. They may be superficial, intermediate or deep.
Cosmetic skin care should always be present in our esthetic practice; it will enhance and 
maintain our results and is considered to be the single most important measure in skin anti-
aging. The regimen should consider adequate detergent, day and night time topical prepara-
tions and should be adjusted according to the skin type and patients’ habits.
Finally, it is important to consider the physiological implications of the patient BTX resistant. 
For many of them, it is considered a major loss, especially if they were used to regular treat-
ments and had experimented its benefits for a long time. It is suggested to listen to the patient 
fears and to provide alternative options, to avoid helpless or abandon feelings. Psychological 
support with specialist is advised if during controls, patients is perceived extremely anxious, 
hesitated or depressed.
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7. Conclusion
Botulinum toxin is one of the best therapeutic weapons available for the treatment of facial 
dynamic wrinkles and we must, if possible, prevent, suspect, diagnose and treat the presence 
of resistance, to perpetuate a safe and efficient use of the product for our patients in the future.
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